ChEMBL Resources

The SARfaris: GPCR, Kinase, ADME

Friday, 23 April 2010

2010 New Drug Approvals - Pt. V - Carglumic acid (Carbaglu)

ATC code: A16AA05

On March 18th, the FDA approved carglumic acid to be marketed under the name Carbaglu as the first specific treatment for a rare form of hyperammonaemia. Carbaglu has been marketed in Europe since 2003. The ATC code is A16AA05.

Carglumic acid is used to treat a deficiency in the enzyme N-Acetyl Glutamate Synthase (NAGS), which leads to acute hyperammonaemia. NAGS deficiency is a very rare genetic disorder where a single base deletion in chromosome 17q leads to a frameshift mutation in the NAGS gene (UniProt: Q8N159) (this leads to a non-functional protein product). It is estimated that it occurs in one of ~50,000 births and due to the rareness of this autosomal recessive disorder, Carbaglu is considered as an orphan drug. NAGS deficiency manifests within the first week of life with unspecific symptoms such as failure to feed, low body temperature and sleepiness. If left untreated, the accumulation of ammonia (hyperammonemia) in the patient's blood causes lethargy, vomiting, deep coma and fatal cerebral oedema.

The catalytic product of NAGS is N-acetylglutamate, the endogenous activator of the first step in the urea cycle. Individuals with NAGS deficiency have low levels of N-acetylglutamate and the elimination of ammonia through the urea cycle is therefore impaired. Carglumic acid is a close structural analogue of N-acetylglutamate but is more stable against enzymatic hydrolysis and penetrates mitochondrial membranes more efficiently. Like N-acetylglutamate, Carglumic acid activates the urea cycle (via activating the mitochondrial protein Carbamoyl Phosphate Synthase 1 (CPS 1) (UniProt: P31327), thus keeping ammonia blood levels low.

Carglumic acid is administered orally and the daily dose is to be adjusted between 100 and 250mg/kg (for a typical 70kg adult, this corresponds to a daily dose of 7g, or ~37 The apparent Volume of distribution (Vd) is 2657L, and has a mean elimination half-life (t1/2) of 5.6 hr, and a total clearance of 5.7 L.min-1.

Carbaglu was developed by Orphan Europe and is marketed in the United States by Recordati S.p.A.
The full prescribing information for Carbaglu can be found here.
Molecular Formula: C7H12N2O5
Molecular Weight: 204.18058
InChI (v1.02b): InChI=1/C7H12N2O5/c8-7(14)9-4(6(12)13)2-1-3-5(10)11/h4H,1-3H2,(H,10,11)(H,12,13)(H3,8,9,14)/t4-/m0/s1

No comments: